Hematopoietic Stem Cell Transplantation
177
33
37
80
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
14 trials with published results (8%)
Research Maturity
80 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.7%
3 terminated out of 177 trials
96.4%
+9.8% vs benchmark
12%
21 trials in Phase 3/4
18%
14 of 80 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 80 completed trials
Clinical Trials (177)
HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT
Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
Metagenomics Next-generation Sequencing Approach to Detect Microbial DNA/RNA Overtime in Individuals Undergoing Hematopoietic Stem Cell Transplant
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy
Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
Xiaochaihu Granules for Depression After Allogeneic Hematopoietic Stem Cell Transplantation
Immunomonitoring After Hematopoietic Stem Cell Transplantation
Peer Support Intervention for Caregivers of Patients Undergoing HSCT
Oral, Chemosensory and Trigeminal Functions in Allo-HSCT
Glucose Control In Hematopoetic Stem Cell Transplant
Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation
Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT